Advertisement


Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck

2024 Multidisciplinary Head and Neck Cancers Symposium

Advertisement

Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II study results showing that patients with locally advanced, unresectable basal cell carcinoma of the head and neck experienced improved quality of life after induction and concurrent vismodegib with curative-intent radiation treatment. According to Dr. Barker, the data on this strategy may provide a beneficial benchmark for clinical practice (Abstract 9).



Related Videos

Head and Neck Cancer

Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance

Eleni M. Rettig, MD, of Brigham and Women’s Hospital, discusses the promising but thus far limited data on using circulating tumor HPV DNA for early detection of HPV-related oropharyngeal cancers, which highlights the importance of developing a reliable biomarker (Poster Abstract 177).

Head and Neck Cancer

Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck

Nabil F. Saba, MD, of Emory University, discusses phase II study results suggesting parenteral administration of TK-90 may be an effective strategy for preventing radiation-induced oral mucositis in patients with squamous cell carcinoma of the head and neck (Abstract 10).

Head and Neck Cancer

Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib

Nabil F. Saba, MD, of Emory University, discusses study findings on 2-year survival rates in patients with recurrent metastatic head and neck squamous cell carcinoma who received pembrolizumab plus cabozantinib. The progression-free survival rate of 32% and the overall survival rate of 55% suggest a durable clinical activity of this combination therapy (Abstract 2).

Head and Neck Cancer

Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC

Marcin R. Dzienis, MBBS, of Australia’s Gold Coast University Hospital, discusses the final analysis of KEYNOTE-B10, a phase IV study in which patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) received a first-line combination regimen of pembrolizumab plus carboplatin and paclitaxel. The regimen demonstrated durable antitumor activity, irrespective of patients’ PD-L1 status (Abstract 3).

Head and Neck Cancer

Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer

Evan M. Graboyes, MD, MPH, of the Medical University of South Carolina, discusses the results of the NDURE study, which explored the delays in starting postoperative radiation therapy in patients with head and neck cancer and ways to improve the timeliness and equity of treatment. Delays in this therapy are associated with higher recurrence and poorer survival in this population (Abstract LBA2).

Advertisement

Advertisement




Advertisement